Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum β-lactamase (ESBL)-producing Escherichia coli

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 11, 2010, Pages 2459-2463

  Oteo, Jesús ^a   Bautista, Verónica ^a   Lara, Noelia ^a   Cuevas, Oscar ^a   Arroyo, Margarita ^a   Fernández, Sara ^a   Lázaro, Edurne ^b   de Abajo, Francisco J ^c   Campos, José ^a,d  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b Ministry of Health   (Spain)

^c HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^d CSIC   (Spain)

Author keywords

CTX M 15; Phylogroup B2; Serotype O25b

Indexed keywords

EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN;

AGED; AMBULATORY CARE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; COMMUNITY CARE; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; BETA-LACTAMASES; DNA FINGERPRINTING; DRUG RESISTANCE, BACTERIAL; DRUG UTILIZATION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FOSFOMYCIN; GENOTYPE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PHYLOGENY; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA; SEROTYPING; SPAIN; URINARY TRACT INFECTIONS;

EID: 77957878825     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq346     Document Type: Article

References (11)

1. Oteo J, Pérez-Vázquez M, Campos J. Extended-spectrum β-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis 2010; 23: 320-6.
2. Falagas ME, Kastoris AC, Kapaskelis AM et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10: 43-50.
3. Falagas ME, Vouloumanou EK, Togias AG et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. J Antimicrob Chemother 2010; 65: 1862-77.
4. Galatti L, Sessa A, Mazzaglia G et al. Antibiotic prescribing for acute and recurrent cystitis in primary care: a 4 year descriptive study. J Antimicrob Chemother 2006; 57: 551-6.
5. Knottnerus BJ, Nys S, ter Riet G et al. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands? J Antimicrob Chemother 2008; 62: 356-9.
6. Oteo J, Orden B, Bautista V et al. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. J Antimicrob Chemother 2009; 64: 712-7.
7. European Society of Clinical Microbiology and Infectious Diseases. http://www.eucast.org/clinical_breakpoints/ (15 June 2010, data last accessed).
8. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification and DDD Assignment. Oslo, Norway: WHO, 2005.
9. Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol 2000; 66: 4555-8.
10. Clermont O, Lavollay M, Vimont S et al. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent phylogenetic subgroup. J Antimicrob Chemother 2008; 61: 1024-8.
11. Wachino J, Yamane K, Suzuki S et al. Prevalence of fosfomycin resistance among CTX-M-producing Escherichia coli clinical isolates in Japan and identification of novel plasmid-mediated fosfomycin-modifying enzymes. Antimicrob Agents Chemother 2010; 54: 3061-4.